Literature DB >> 34023224

Diagnostic Precision in the Detection of Mild Cognitive Impairment: A Comparison of Two Approaches.

Andrea M Weinstein1, Swathi Gujral2, Meryl A Butters3, Christopher R Bowie4, Corinne E Fischer5, Alastair J Flint6, Nathan Herrmann7, James L Kennedy8, Linda Mah9, Shima Ovaysikia10, Bruce G Pollock8, Tarek K Rajji8, Benoit H Mulsant8.   

Abstract

OBJECTIVE: This study compared diagnostic rates and clinical predictors of discrepancies between diagnoses conferred via: 1) a comprehensive neuropsychological evaluation and National Institute on Aging-Alzheimer's Association (NIA-AA) criteria versus 2) a cognitive screener and Diagnostic Statistical Manual of Mental Disorders (DSM-5) criteria.
DESIGN: Cross-sectional examination of baseline data from the Prevention of Alzheimer's dementia (AD) using Cognitive remediation and transcranial direct current stimulation in Mild Cognitive Impairment (MCI) and Depression (PACt-MD; ClinicalTrials.gov Identifier: NCT02386670) trial.
SETTING: Five geriatric psychiatry and memory clinics located at academic hospitals affiliated with the Department of Psychiatry, University of Toronto. PARTICIPANTS: Older adults (N = 431) with a history of major depressive disorder (MDD) in remission, MCI, or both. MEASUREMENTS: Main outcome was a comparison of NIA-AA diagnostic rates of MCI or dementia versus DSM-5 rates of mild or major neurocognitive disorder. Secondary analyses examined demographic, race, gender, premorbid intellectual ability, psychosocial, health-related, and genetic predictors of discrepancy between DSM-5 and NIA-AA diagnoses.
RESULTS: There were 103 (23.8%) discrepant cases, with most (91; 88.3%) of these discrepant cases reflecting more impairment with the detailed neuropsychological testing and NIA-AA criteria. Discrepancies were more likely in individuals with a history of MDD or who had at least one ApoE4 allele.
CONCLUSION: The NIA-AA criteria, in conjunction with comprehensive neuropsychological testing, identified a greater prevalence of cognitive impairment than DSM-5 criteria, in conjunction with the Montreal Cognitive Assessment. Detailed neuropsychological evaluations are recommended for older adults who have a history of MDD or a genetic vulnerability to dementia.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Alzheimer's; cognition; dementia; mild cognitive impairment

Mesh:

Year:  2021        PMID: 34023224      PMCID: PMC8720569          DOI: 10.1016/j.jagp.2021.04.004

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  23 in total

1.  Normative data on computerized paced auditory serial addition task performance.

Authors:  S A Wingenfeld; D J Holdwick; J L Davis; B B Hunter
Journal:  Clin Neuropsychol       Date:  1999-08       Impact factor: 3.535

2.  The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

3.  Trail Making Test A and B: normative data stratified by age and education.

Authors:  Tom N Tombaugh
Journal:  Arch Clin Neuropsychol       Date:  2004-03       Impact factor: 2.813

4.  ApoE genotype and family history in patients with dementia and cognitively intact spousal controls.

Authors:  Maria Zintl; Gerd Schmitz; Göran Hajak; Hans-Hermann Klünemann
Journal:  Am J Alzheimers Dis Other Demen       Date:  2009-04-16       Impact factor: 2.035

5.  The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.

Authors:  Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow
Journal:  J Am Geriatr Soc       Date:  2005-04       Impact factor: 5.562

6.  The measurement of everyday cognition (ECog): scale development and psychometric properties.

Authors:  Sarah Tomaszewski Farias; Dan Mungas; Bruce R Reed; Deborah Cahn-Weiner; William Jagust; Kathleen Baynes; Charles Decarli
Journal:  Neuropsychology       Date:  2008-07       Impact factor: 3.295

7.  Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale.

Authors:  M D Miller; C F Paradis; P R Houck; S Mazumdar; J A Stack; A H Rifai; B Mulsant; C F Reynolds
Journal:  Psychiatry Res       Date:  1992-03       Impact factor: 3.222

8.  Normative data for equivalent, parallel forms of the Judgment of Line Orientation Test.

Authors:  J L Woodard; R H Benedict; T A Salthouse; J P Toth; D J Zgaljardic; H E Hancock
Journal:  J Clin Exp Neuropsychol       Date:  1998-08       Impact factor: 2.475

9.  Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type.

Authors:  J C Morris
Journal:  Int Psychogeriatr       Date:  1997       Impact factor: 3.878

10.  Neuropsychological functioning in the acute and remitted States of late-life depression.

Authors:  Aaron M Koenig; Isaac J DeLozier; Michelle D Zmuda; Megan M Marron; Amy E Begley; Stewart J Anderson; Charles F Reynolds; Steven E Arnold; James T Becker; Meryl A Butters
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.